Patient Guide: A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 10 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT05483868
Status: 🟢 Enrolling Now
Condition: Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer (&Amp;#34;NMIBC&Amp;#34;) Unresponsive/Intolerant to BCG, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms, Non-Muscle Invasive Bladder Urothelial Carcinoma, Urothelial Carcinoma Bladder
Phase: PHASE1

Where You Can Participate

This study is available at 10 locations across the country.

Top locations include:
  • • Little Rock, Arkansas
  • • Santa Monica, California
  • • The Bronx, New York
  • • And 7 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer - Join Clinical Trial NCTNCT05483868

How to Join This Clinical Trial - NCTNCT05483868

Learn how to participate in this PHASE1 trial studying an investigational therapy for Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer (&Amp;#34;NMIBC&Amp;#34;) Unresponsive/Intolerant to BCG, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms, Non-Muscle Invasive Bladder Urothelial Carcinoma, Urothelial Carcinoma Bladder. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer (&Amp;#34;NMIBC&Amp;#34;) Unresponsive/Intolerant to BCG, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms, Non-Muscle Invasive Bladder Urothelial Carcinoma, Urothelial Carcinoma Bladder. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer (&Amp;#34;NMIBC&Amp;#34;) Unresponsive/Intolerant to BCG, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms, Non-Muscle Invasive Bladder Urothelial Carcinoma, Urothelial Carcinoma Bladder
Treatment Being Tested
Investigational treatment
Study Phase
PHASE1 - Early safety study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT05483868 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 10 locations. Find a study site near you:

Clinical Research Site

Little Rock, Arkansas 72211 - United States

Status: TERMINATED

Clinical Research Site

Santa Monica, California 90404 - United States

Status: RECRUITING

Clinical Research Site

The Bronx, New York 10461 - United States

Status: RECRUITING

Clinical Research Site

Myrtle Beach, South Carolina 29272 - United States

Status: RECRUITING

Clinical Research Site

Nashville, Tennessee 37209 - United States

Status: SUSPENDED

Clinical Research Site

Dallas, Texas 75251 - United States

Status: RECRUITING

Clinical Research Site

Houston, Texas 77030 - United States

Status: RECRUITING

Clinical Research Site

San Antonio, Texas 78229 - United States

Status: RECRUITING

Clinical Research Site

San Antonio, Texas 78229 - United States

Status: RECRUITING

Clinical Research Site

San Antonio, Texas 78240 - United States

Status: RECRUITING

How to Enroll in This Study

To learn more about participating in this PHASE1 clinical trial for Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer (&Amp;#34;NMIBC&Amp;#34;) Unresponsive/Intolerant to BCG, NMIBC, Non-Muscle Invasive Bladder Carcinoma, Non-Muscle Invasive Bladder Neoplasms, Non-Muscle Invasive Bladder Urothelial Carcinoma, Urothelial Carcinoma Bladder:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships